XOMA Royalty Corporation

Pierre Fabre may have shunned the spotlight but the French group, which is arguably best known for its significant beauty care arm, is making major strides in becoming an attractive partner for innov

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Biogen’s Pact With AbCellera Will Focus

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie To Pay $48m Up Front For Preclin

Follow-on public offerings (FOPOs) have become increasingly difficult to execute in the current financial market climate with public biopharmaceutical company valuations plummeting, so many drug devel